Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Disease mechanisms

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Background KLOTHO -VS heterozygosity ( KL -VSHET) and soluble α-Klotho (sαKl) protein interfere with Alzheimer's disease (AD) pathophysiology, but the specific relationships remain unclear. This study explored these associations across the AD continuum, focusing on core AD biomarkers and markers of neurodegeneration, neuroinflammation, and synaptic dysfunction. Objective We investigated whether 1) KL -VSHET is associated with lower AD biomarker burden (Aβ 42 , Aβ 42/40 ratio, P-tau181, T-tau) and neurodegeneration (NfL); 2) sαKl relates to AD biomarkers, neurodegeneration (NfL), neuroinflammation (GFAP), and synaptic dysfunction (Ng); 3) associations vary by APOE ε4 status and clinical subgroup. Methods Participants (n = 223) were categorized as cognitively healthy (n = 38), aMCI-AD (n = 94), and AD dementia (n = 91). KLOTHO genotyping was available for 128 participants; 138 had cerebrospinal fluid (CSF) and serum sαKl measurements; and 42 had both. Multiple linear regression evaluated associations between KL -VSHET, sαKl levels, and biomarkers, stratified by APOE ε4 status and clinical subgroup. Results Overall, the associations between KL -VSHET and higher CSF Aβ 42 and Aβ 42/40 ratio were non-significant ( p s ≥ 0.059) except when restricted to APOE ε4 carriers only (β = 0.11, p = 0.008 and β = 0.16, p = 0.033, respectively). Within clinical subgroups, KL -VSHET was positively associated with Aβ 42/40 ratio only in aMCI-AD (β = 0.23, p = 0.034). No significant associations were observed between KL -VSHET and tau biomarkers or NfL. For sαKl, associations with biomarkers were non-significant except for a negative association of serum sαKl with P-tau181 in aMCI-AD (β = −0.25, p = 0.036) and a positive association with Aβ 42/40 ratio in APOE ε4 non-carriers (β = 0.24 p = 0.047). Conclusions KL -VSHET may help protect against amyloid pathology, particularly in the presence of APOE ε4, and regardless of APOE status in aMCI-AD.

What this study adds

Evidence grade: Low

The record lists 223 participants. In 223 participants across the Alzheimer's continuum, associations between KLOTHO-VS heterozygosity and higher cerebrospinal fluid Aβ42 and Aβ42/40 ratio were non-significant overall, except when restricted to APOE ε4 carriers. This is observational biomarker research and does not show that KLOTHO-VS heterozygosity or α-Klotho protein treats or prevents Alzheimer's disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Katonová, A., Andel, R., Jurasova, V., Veverová, K., Angelucci, F., Maťoška, V., et al. (2025). Associations of KLOTHO-VS heterozygosity and α-Klotho protein with cerebrospinal fluid Alzheimer's disease biomarkers. Journal of Alzheimer s Disease. https://doi.org/10.1177/13872877251326199

Vancouver

Katonová A, Andel R, Jurasova V, Veverová K, Angelucci F, Maťoška V, et al. Associations of KLOTHO-VS heterozygosity and α-Klotho protein with cerebrospinal fluid Alzheimer's disease biomarkers. Journal of Alzheimer s Disease. 2025. doi:10.1177/13872877251326199. PMID: 40112321.

BibTeX

@article{katonova2025-40112321,
  author  = {Katonová, Alžběta and Andel, Ross and Jurasova, Vanesa and Veverová, Kateřina and Angelucci, Francesco and Maťoška, Václav and Hort, Jakub},
  title   = {{Associations of KLOTHO-VS heterozygosity and α-Klotho protein with cerebrospinal fluid Alzheimer's disease biomarkers}},
  journal = {Journal of Alzheimer s Disease},
  year    = {2025},
  doi     = {10.1177/13872877251326199},
  pmid    = {40112321},
  url     = {https://doi.org/10.1177/13872877251326199}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

In 223 participants across the Alzheimer's continuum, associations between KLOTHO-VS heterozygosity and higher cerebrospinal fluid Aβ42 and Aβ42/40 ratio were non-significant overall, except when restricted to APOE ε4 carriers. This is observational biomarker research and does not show that KLOTHO-VS heterozygosity or α-Klotho protein treats or prevents Alzheimer's disease.

Study details

How this study scored 44/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 1 of 7; Citations per year 1 of 5; Impact for its field and year 2 of 6; Cited by studies here 0 of 6; Still being cited 1 of 4; Senior author's track record 3 of 4; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 44 of 100.44 of 100 points earned56 not earned

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of Alzheimer s Disease)
Journal's citation record 2 / 4 Journal of Alzheimer s Disease: journal h-index 218 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 2 / 4 223 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 4 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 1.3 citations a year over 3 year(s) since 2025
Impact for its field and year 2 / 6 Cited 2.2× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 1 / 4 Cited 4 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Jakub Hort: h-index 55 (OpenAlex, whole career)
Institution's track record 1 / 3 Arizona State University: institution h-index 987 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 4 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40112321)
Free to read 2 / 2 Free to read
Total 44 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Disease mechanisms from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Disease mechanisms

See all studies in Disease mechanisms →